Business Combinations - Schedule of Pro Forma Financial Information (Details) - USD ($) $ in Thousands |
12 Months Ended | |
|---|---|---|
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| BioMedomics, Inc | ||
| Business Combination [Line Items] | ||
| Net revenues | $ 115,797 | $ 187,041 |
| Net income loss | (68,964) | (20,889) |
| Sherlock Biosciences | ||
| Business Combination [Line Items] | ||
| Net revenues | 188,126 | 406,381 |
| Net income loss | $ (41,459) | $ 7,992 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after tax, of pro forma income (loss) of combined entity as if acquisition date of business combination occurred as of beginning of period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of pro forma revenue of combined entity as if acquisition date of business combination occurred as of beginning of period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|